Chime Biologics, a biologics contract development and manufacturing organization (CDMO), has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.

LBL-007 is a novel antibody targeting the LAG-3 pathway developed independently by Leads Biolabs.

Previously, Leads Biolabs and BeiGene reached an authorization and cooperation agreement. Leads Biolabs grants LBL-007 exclusive global development and production license to BeiGene, as well as a commercial manufacturing license outside China.

Leads Biolabs has entrusted Chime Biologics with the file supporting work related to the production of LBL-007 project and clinical trial materials in mainland China. Now, the project is progressing into clinical phase II stage. Leads Biolabs is evaluating the safety and efficacy of anti-LAG-3 (lymphocyte activating gene-3) antibody LBL-007 in the treatment of advanced or metastatic melanoma.

Chime Biologics will provide support for clinical development and manufacturing of clinical trial materials to facilitate multiple clinical trials. The indications encompass colorectal cancer, non-small cell lung cancer, head, and neck squamous cell carcinoma, as well as other solid tumors.

The three parties have established a comprehensive strategic partnership to help rapidly advance multiple clinical studies and the global development distribution of LBL-007.